Physiological age vs chronological age6/28/2023 ![]() This and other frailty indices take a top-down, systems based view of aging that is cognizant of the integrated function of the complex aging system. FI 34 has been directly compared to various metrics based on DNA methylation as a predictor of mortality, demonstrating that it outperforms them uniformly. These differences give rise to specific, testable models regarding healthy aging, which involve cell and tissue damage and mitochondrial metabolism. FI 34 has also been useful in describing the metabolic characteristics of this phenotype, revealing both sex and genetic differences. Thus, it has been used to identify a genomic region on chromosome 12 associated with healthy aging. It readily depicts different patterns and trajectories of aging, and it is moderately heritable. FI 34 increases exponentially with age reflecting decline in health and function ability. Among them are frailty indices, one of which called FI 34 is discussed here in greater detail. ![]() Several quantitative measures of biological age have been developed. Any measure of biological age must be better than chronological age at predicting mortality. Tulane Center for Aging, Department of Medicine, Tulane University Health Sciences Center, Tulane School of Medicine, New Orleans, LA, United Statesīiological age is a concept that takes into account the heterogeneity of the aging process in different individuals that results in differences in survival and variations in relative health.All rights reserved.Īging Biomarker Consortium Bao H, Cao J, Chen M, Chen M, Chen W, Chen X, Chen Y, Chen Y, Chen Y, Chen Z, Chhetri JK, Ding Y, Feng J, Guo J, Guo M, He C, Jia Y, Jiang H, Jing Y, Li D, Li J, Li J, Liang Q, Liang R, Liu F, Liu X, Liu Z, Luo OJ, Lv J, Ma J, Mao K, Nie J, Qiao X, Sun X, Tang X, Wang J, Wang Q, Wang S, Wang X, Wang Y, Wang Y, Wu R, Xia K, Xiao FH, Xu L, Xu Y, Yan H, Yang L, Yang R, Yang Y, Ying Y, Zhang L, Zhang W, Zhang W, Zhang X, Zhang Z, Zhou M, Zhou R, Zhu Q, Zhu Z, Cao F, Cao Z, Chan P, Chen C, Chen G, Chen HZ, Chen J, Ci W, Ding BS, Ding Q, Gao F, Han JJ, Huang K, Ju Z, Kong QP, Li J, Li J, Li X, Liu B, Liu F, Liu L, Liu Q, Liu Q, Liu X, Liu Y, Luo X, Ma S, Ma X, Mao Z, Nie J, Peng Y, Qu J, Ren J, Ren R, Song M, Songyang Z, Sun YE, Sun Y, Tian M, Wang S, Wang S, Wang X, Wang X, Wang YJ, Wang Y, Wong CCL, Xiang AP, Xiao Y, Xie Z, Xu D, Ye J, Yue R, Zhang C, Zhang H, Zhang L, Zhang W, Zhang Y, Zhang YW, Zhang Z, Zhao T, Zhao Y, Zhu D, Zou W, Pei G, Liu GH. This review summarizes the current knowledge on biological age biomarkers, factors influencing biological aging, and antiaging interventions, with a focus on vascular aspects of the aging process and its cardiovascular disease related manifestations.Īntiaging therapy biological age biological age biomarkers chronological age vascular disease.Ĭopyright © 2020 The Authors. However, strategies to extend health span and life span require understanding of interindividual differences in age-dependent functional decline, known as biological aging. Studies in experimental models and humans have identified 9 highly interconnected hallmark processes driving mammalian aging. In a progressively aging population, it is essential to develop early-life biomarkers that efficiently identify individuals who are at high risk of developing accelerated vascular damage, with the ultimate goal of improving primary prevention and reducing the health care and socioeconomic impact of age-related cardiovascular disease. Electronic address: is the main risk factor for vascular disease and ensuing cardiovascular and cerebrovascular events, the leading causes of death worldwide. 4 Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain. ![]() Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, New York. Wiener Cardiovascular Institute/Marie-Josée and Henry R. 3 Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain The Zena and Michael A.2 Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain.1 Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain.
0 Comments
Leave a Reply. |